Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
5 studies found for:    PM01183 | Open Studies
Show Display Options
Rank Status Study
1 Recruiting A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer
Condition: Breast Cancer
Intervention: Drug: PM01183
2 Recruiting Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Patients With Selected Solid Tumors
Condition: Advanced Solid Tumors
Interventions: Drug: lurbinectedin ( PM01183);   Drug: Irinotecan
3 Recruiting Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors
Condition: Advanced Solid Tumors
Intervention: Drug: lurbinectedin (PM01183)
4 Recruiting Study to Evaluate PM01183 in Combination With Olaparib in Advanced Solid Tumors
Condition: Advanced Solid Tumors.
Intervention: Drug: PM01183 + olaparib
5 Recruiting Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) Versus Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients With Small-Cell Lung Cancer
Condition: Small-cell Lung Cancer
Interventions: Drug: Lurbinectedin (PM01183);   Drug: Doxorubicin (DOX);   Drug: Cyclophosphamide (CTX);   Drug: Vincristine (VCR);   Drug: Topotecan

Study has passed its completion date and status has not been verified in more than two years.